MiNK Therapeutics collaborates with C-Further consortium to develop PRAME-targeted TCR-engineered iNKT cell therapy for paediatric cancers, aiming to deliver innovative immunotherapy options for children with limited treatment alternatives.
LifeArc | 12/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy